血液系统恶性肿瘤患者的抗真菌预防：重新评估 - Suppr

Suppr

超能文献

Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.

作者信息

Uzun O, Anaissie E J

机构信息

Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

出版信息

Blood. 1995 Sep 15;86(6):2063-72.

PMID:7662953

Abstract

摘要

相似文献

Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.

Blood. 1995 Sep 15;86(6):2063-72.

Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.

Blood. 2003 May 1;101(9):3365-72. doi: 10.1182/blood-2002-05-1356. Epub 2002 Aug 29.

[Current indications for voriconazole in onco-hematological patients].

Rev Iberoam Micol. 2007 Sep 30;24(3):213-6. doi: 10.1016/s1130-1406(07)70045-1.

[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].

Rev Clin Esp. 1995 Oct;195 Suppl 3:31-7.

Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.

Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S15-20.

[Prevention of fungal infections in children and adolescents with cancer].

Klin Padiatr. 2001 Sep;213 Suppl 1:A50-68. doi: 10.1055/s-2001-17502.

Fungal infections: current diagnosis and treatment.

Hematol J. 2004;5 Suppl 3:S59-62. doi: 10.1038/sj.thj.6200424.

Modern antifungal therapy for neutropenic fever.

Curr Hematol Malig Rep. 2006 Jun;1(2):95-100. doi: 10.1007/s11899-006-0029-0.

Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.

Prescrire Int. 2004 Feb;13(69):13-6.

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Ann Hematol. 2014 Jan;93(1):13-32. doi: 10.1007/s00277-013-1867-1. Epub 2013 Sep 12.

引用本文的文献

Health-care utilization and outcomes of patients at high risk of invasive fungal infection.

Clinicoecon Outcomes Res. 2018 Jul 12;10:371-387. doi: 10.2147/CEOR.S162964. eCollection 2018.

Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00355-18. Print 2018 Aug.

Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Curr Oncol Rep. 2017 Mar;19(3):18. doi: 10.1007/s11912-017-0574-9.

Antifungal Prophylaxis in Immunocompromised Patients.

Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016040. doi: 10.4084/MJHID.2016.040. eCollection 2016.

Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Blood. 2015 Dec 24;126(26):2790-7. doi: 10.1182/blood-2015-07-627323. Epub 2015 Oct 26.

Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.

Support Care Cancer. 2011 Oct;19(10):1657-65. doi: 10.1007/s00520-010-0998-3. Epub 2010 Sep 10.

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

Pharmacoeconomics. 2008;26(1):75-90. doi: 10.2165/00019053-200826010-00007.

The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida.

Curr Infect Dis Rep. 2006 Nov;8(6):442-8. doi: 10.1007/s11908-006-0018-4.

Pneumonia in neutropenic patients.

Eur Radiol. 2004 Feb;14(2):256-71. doi: 10.1007/s00330-003-1985-6. Epub 2003 Jul 24.

Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.

Drugs Aging. 2000 Nov;17(5):339-51. doi: 10.2165/00002512-200017050-00002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.

作者信息

Uzun O, Anaissie E J

机构信息

Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

出版信息

Blood. 1995 Sep 15;86(6):2063-72.

PMID:7662953

Abstract

摘要

相似文献

Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.

Blood. 1995 Sep 15;86(6):2063-72.

Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.

Blood. 2003 May 1;101(9):3365-72. doi: 10.1182/blood-2002-05-1356. Epub 2002 Aug 29.

[Current indications for voriconazole in onco-hematological patients].

Rev Iberoam Micol. 2007 Sep 30;24(3):213-6. doi: 10.1016/s1130-1406(07)70045-1.

[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].

Rev Clin Esp. 1995 Oct;195 Suppl 3:31-7.

Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.

Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S15-20.

[Prevention of fungal infections in children and adolescents with cancer].

Klin Padiatr. 2001 Sep;213 Suppl 1:A50-68. doi: 10.1055/s-2001-17502.

Fungal infections: current diagnosis and treatment.

Hematol J. 2004;5 Suppl 3:S59-62. doi: 10.1038/sj.thj.6200424.

Modern antifungal therapy for neutropenic fever.

Curr Hematol Malig Rep. 2006 Jun;1(2):95-100. doi: 10.1007/s11899-006-0029-0.

Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.

Prescrire Int. 2004 Feb;13(69):13-6.

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Ann Hematol. 2014 Jan;93(1):13-32. doi: 10.1007/s00277-013-1867-1. Epub 2013 Sep 12.

引用本文的文献

Health-care utilization and outcomes of patients at high risk of invasive fungal infection.

Clinicoecon Outcomes Res. 2018 Jul 12;10:371-387. doi: 10.2147/CEOR.S162964. eCollection 2018.

Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00355-18. Print 2018 Aug.

Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Curr Oncol Rep. 2017 Mar;19(3):18. doi: 10.1007/s11912-017-0574-9.

Antifungal Prophylaxis in Immunocompromised Patients.

Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016040. doi: 10.4084/MJHID.2016.040. eCollection 2016.

Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Blood. 2015 Dec 24;126(26):2790-7. doi: 10.1182/blood-2015-07-627323. Epub 2015 Oct 26.

Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.

Support Care Cancer. 2011 Oct;19(10):1657-65. doi: 10.1007/s00520-010-0998-3. Epub 2010 Sep 10.

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

Pharmacoeconomics. 2008;26(1):75-90. doi: 10.2165/00019053-200826010-00007.

The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida.

Curr Infect Dis Rep. 2006 Nov;8(6):442-8. doi: 10.1007/s11908-006-0018-4.

Pneumonia in neutropenic patients.

Eur Radiol. 2004 Feb;14(2):256-71. doi: 10.1007/s00330-003-1985-6. Epub 2003 Jul 24.

Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.

Drugs Aging. 2000 Nov;17(5):339-51. doi: 10.2165/00002512-200017050-00002.